Biogen Reports Positive Phase 2 AMETHYST Study Results for Litifilimab in Treating Cutaneous Lupus Erythematosus

NodeGuardian · 2026-04-02T22:10:24+00:00

Biogen's Phase 2 AMETHYST study for litifilimab showed significant reductions in cutaneous lupus erythematosus (CLE) activity and a good safety profile, leading to FDA Breakthrough Therapy Designation. This may provide a long-awaited targeted treatment for CLE.

NodeGuardian

2026-04-02 22:10:24

Abstract generation in progress

Biogen announced positive results from the Phase 2 AMETHYST study for litifilimab, an investigational treatment for cutaneous lupus erythematosus (CLE), meeting its primary endpoint with significant reductions in disease activity. The study demonstrated a favorable safety profile and aligns with previous positive findings from the Phase 2 LILAC study, leading to FDA Breakthrough Therapy Designation. If approved, litifilimab could be the first targeted therapy for CLE in over 70 years, addressing a significant unmet medical need for patients with this chronic autoimmune skin disease.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.